Aurion Biotech Reports Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 in Corneal Endothelial Disease Aurion Biotech, a clinical-stage regenerative medicine company dedicated to restoring vision for millions of patients worldwide, today announced encouraging 12-month results from its…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
Ono Pharmaceutical Announces Two-Year Results from Phase 3 MOTION Study of Vimseltinib in TGCT at ESMO 2025 Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that two-year efficacy and safety results from the…
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Shows Durable 5-Year Survival Benefit Over Chemotherapy in Advanced Endometrial Carcinoma Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced updated five-year follow-up data from the pivotal Phase…
Genmab Reports Promising New Data Showing Rina-S® Demonstrates Strong Anti-Tumor Activity in Advanced Endometrial Cancer Genmab A/S (Nasdaq: GMAB) announced new and encouraging results from its Phase 1/2 RAINFOL™-01 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha…
Researchers at General Atomics (GA) are playing a pivotal role in addressing one of the most complex and persistent challenges in the pursuit of fusion energy — sustaining and controlling the high-energy fuel that powers fusion reactions. In a landmark…
The U.S. public sector is undergoing a sweeping transformation in how it envisions, builds, and operates its digital workplaces. A new research report by Information Services Group (ISG) (Nasdaq: III), a global AI-focused technology research and advisory firm, reveals that…
Evvy, the world’s leading platform leveraging the vaginal microbiome to improve women’s health outcomes, today announced record growth and compelling new data demonstrating the transformative impact of its platform. Evvy now serves over 75,000 patients and partners with more than…
EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced updated long-term results from the global Phase 3 MANEUVER trial, evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor, for the treatment…
Water- en Energiebedrijf Aruba N.V. (WEB) and Seven Seas Water Group, a leading multinational provider of Water-as-a-Service® (WaaS®) solutions, have officially broken ground on a new state-of-the-art seawater reverse osmosis (SWRO) desalination plant in Aruba. The project marks a major…